Last reviewed · How we verify
MIT-001 plus CCRT — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
MIT-001 plus CCRT (MIT-001 plus CCRT) — MitoImmune Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MIT-001 plus CCRT TARGET | MIT-001 plus CCRT | MitoImmune Therapeutics | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MIT-001 plus CCRT CI watch — RSS
- MIT-001 plus CCRT CI watch — Atom
- MIT-001 plus CCRT CI watch — JSON
- MIT-001 plus CCRT alone — RSS
Cite this brief
Drug Landscape (2026). MIT-001 plus CCRT — Competitive Intelligence Brief. https://druglandscape.com/ci/mit-001-plus-ccrt. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab